鲲石生物获 5000 万人民币 A 轮融资，加速巨噬细胞药物创新

Core Viewpoint - Kunshi Biotech has successfully completed a Series A financing round of 50 million RMB to advance its leading macrophage drug research and clinical transformation, particularly focusing on its third-generation CAR-M targeting HER2 pipeline and preclinical studies for pancreatic and lung cancers [1] Group 1: Financing and Development - The recent financing will primarily support the construction of the company's leading macrophage drug platform and accelerate the IND application and phase I clinical progress of its self-developed third-generation CAR-M targeting HER2 pipeline [1] - The successful completion of this financing reflects the capital market's high recognition of the company's innovation capabilities and research progress in the macrophage drug field [1] Group 2: Technological Innovations - Kunshi Biotech has developed four unique technological platforms that address core challenges in the autologous CAR-M therapy, including low transduction efficiency, high costs, long cycles, and weak anti-tumor capabilities [2] - The company's proprietary macrophage-specific viral modification technology has improved the transduction efficiency of adenoviruses and lentiviruses to over 90%, solving the industry's low gene delivery efficiency issue [3] - The third-generation CAR-M developed by Kunshi is the first of its kind globally, incorporating cytokines necessary for the autologous proliferation and activation of macrophages, promoting long-term survival and altering the tumor microenvironment [4] Group 3: Clinical Progress and Efficacy - Kunshi Biotech has established multiple preclinical pipelines targeting major diseases such as solid tumors and chronic diseases, with the RR-M01 pipeline for HER2-positive solid tumors showing promising safety and preliminary efficacy [6] - The RR-M01 injection has demonstrated good safety and encouraging preliminary efficacy in advanced solid tumor patients who were ineffective or intolerant to DS-8201 (trastuzumab deruxtecan), achieving a disease control rate (DCR) of 71.4% [7] - The first subject treated with a single dose of RR-M01 in December 2023 has achieved a progression-free survival (PFS) of 23 months without any other anti-tumor treatment, indicating long-term and high-quality disease control [8] Group 4: Company Vision and Future Plans - The founder of Kunshi Biotech expressed gratitude to shareholders for their support, emphasizing that this financing is a key milestone for the company's development [10] - The company aims to focus on the frontier of macrophage drugs, tackle the core challenges in solid tumor treatment, and push for the commercialization of innovative therapies that are safe, effective, and accessible to cancer patients [10]